Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.
Hosted on MSN3mon
NMO Drug Looks Good for IgG4-Related DiseaseWASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of ...
Amgen (NASDAQ:AMGN) added that a Phase 3 trial called MITIGATE for Uplizna in the treatment of IgG4-related disease met its ...
Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV ...
The company is now waiting for the results of the INDIGO trial in IgG4-RD in 2025, aiming to become the first FDA-approved treatment for the progressive, fibroinflammatory disease, which can cause ...
The systemic disease of which AIP is a part has been called IgG4-related systemic diseases. AIP mimics pancreatic cancer and it is critically important to distinguish between the two diseases.
Children with peanut allergy using the Viaskin peanut patch (VP250) may experience greater clinical benefit with long-term use.
The properties of the different IgG isotypes should be considered in developing therapeutic antibodies. To address this problem, antibody engineers introduced a serine-to-proline substitution that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results